Agios Pharmaceuticals, Inc. (AGIO)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$33.10-0.09%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · AGIO
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | ||||||||||||||
| Revenues | 98.3 | 54.0 | 36.5 | 26.8 | 14.2 | 0.0 | 0.0 | 117.9 | 94.4 | 43.0 | — | — | 65.4 | 25.5 |
| Total Revenues | — | — | — | — | — | — | — | — | — | 43.0 | — | — | 65.4 | 25.5 |
| Cost of Revenues | 7.9 | 6.3 | 4.2 | 2.9 | 1.7 | 0.0 | 0.0 | 1.3 | 1.4 | — | — | — | — | — |
| Operating Expenses & Income | ||||||||||||||
| Selling, General & Admin | 192.7 | 180.3 | 156.8 | 119.9 | 121.7 | 121.4 | 115.1 | 102.0 | 114.1 | — | — | — | — | — |
| R&D Expenses | 356.8 | 339.5 | 301.3 | 295.5 | 279.9 | 257.0 | 220.8 | 214.3 | 341.3 | 292.7 | 220.2 | 141.8 | 100.4 | 54.5 |
| Operating Income | (459.0) | (472.1) | (425.7) | (391.5) | (389.0) | (378.4) | (335.9) | (316.3) | (362.5) | (320.8) | (201.0) | (118.7) | (54.1) | (38.9) |
| Earnings from Continuing Operations | ||||||||||||||
| Interest & Investment Income | — | — | — | — | 12.8 | 0.8 | 6.6 | 14.9 | 16.5 | 6.1 | 2.5 | 1.0 | 0.2 | 0.1 |
| EBT, Incl. Unusual Items | — | (413.8) | 718.0 | (352.1) | (231.8) | (356.5) | (327.4) | (411.5) | (346.0) | (314.7) | (198.5) | (117.7) | (53.9) | (38.8) |
| Income Tax Expense | — | (1.0) | 44.2 | 0.0 | 0.0 | — | — | 0.0 | 0.0 | 0.0 | (0.4) | (0.4) | (0.4) | 0.6 |
| Net Income | ||||||||||||||
| Net Income | (411.5) | (412.8) | 673.7 | (352.0) | (232.0) | 1,605.0 | (327.4) | (411.5) | (346.0) | (314.7) | (198.5) | (117.7) | (53.5) | (39.4) |
| Per Share | ||||||||||||||
| Basic EPS | (6.92) | (7.12) | 11.86 | (6.33) | (4.23) | 26.55 | (4.74) | — | — | — | — | — | — | — |
| Diluted EPS | (6.92) | (7.12) | 11.64 | (6.33) | (4.23) | 26.55 | (4.74) | — | — | — | — | — | — | — |
| Revenue per Share | 1.65 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Basic Weighted Avg Shares | 59.5 | 58.0 | 56.8 | 55.7 | 54.8 | 60.4 | 69.0 | — | — | — | — | — | — | — |
| Diluted Weighted Avg Shares | 59.5 | 58.0 | 57.9 | 55.7 | 54.8 | 60.4 | 69.0 | — | — | — | — | — | — | — |
| Supplemental | ||||||||||||||
| EBITDA | — | — | — | — | — | — | — | (308.2) | — | — | — | — | — | — |
| EBIT | (459.0) | (472.1) | (425.7) | (391.5) | (389.0) | (378.4) | (335.9) | (316.3) | (362.5) | (320.8) | (201.0) | (118.7) | (54.1) | (38.9) |
| Effective Tax Rate | — | — | — | 0.0% | 0.0% | — | — | 0.0% | 0.0% | 0.0% | 0.2% | 0.4% | 0.8% | -1.5% |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.